Proposed Fundraising to raise up to £5.13 million

Summary by AI BETAClose X

Arecor Therapeutics plc announced a proposed fundraising to raise up to £5.13 million through a placing of new ordinary shares at 68 pence per share, with an additional conditional retail offer for existing UK shareholders. The funds will strengthen the balance sheet for partnership negotiations with insulin pump companies, extend the cash runway to December 2027, and support critical insulin development activities, including data generation for a Phase 2 Investigational New Drug application. The issue price represents a premium to the 60-day volume-weighted average price, and the new shares will represent approximately 20.0% of the existing ordinary share capital upon full subscription.

Disclaimer*

UK 100

Latest directors dealings